Press Release: Elevance Health Expands Virtual Assistant To Help Members Navigate Healthcare With Confidence

Check out the companies making headlines this week:

Deere : Agricultural and construction machinery company Deere fell by 5.3% on Wednesday after the company lowered its full-year earnings guidance during its third-quarter report, signaling persistent challenges in the agricultural market. See our full article here.

Is now the time to buy Deere? Access our full analysis report here.

Marvell Technology : Networking chips designer Marvell Technology rose by 4.9% on Wednesday after several analysts updated their views on the company's stock. See our full article here.

Is now the time to buy Marvell Technology? Access our full analysis report here.

Elevance Health : Health insurance provider Elevance Health rose by 2.1% on Monday after reports indicated the White House was preparing to unveil a health policy framework that would extend Affordable Care Act (ACA) premium subsidies for two years. See our full article here.

Is now the time to buy Elevance Health? Access our full analysis report here.

Align Technology : Dental technology company Align Technology rose by 6.2% on Tuesday after the company announced the commercial availability of its Invisalign System with mandibular advancement in the Philippines. See our full article here.

Is now the time to buy Align Technology? Access our full analysis report here.

Tenet Healthcare : Hospital operator Tenet Healthcare rose by 9.7% on Monday after Barclays raised its price target on the company to $240 from $229, signaling continued confidence in the stock. See our full article here.

Is now the time to buy Tenet Healthcare? Access our full analysis report here.

Check out the companies making headlines yesterday:

Meta : Social network operator Meta Platforms rose by 3.5% on Monday after renewed enthusiasm for Alphabet reinvigorated the artificial intelligence trade, propelling a market rebound heading into the Thanksgiving holiday. See our full article here.

Is now the time to buy Meta? Access our full analysis report here.

Tenet Healthcare : Hospital operator Tenet Healthcare rose by 9.7% on Monday after Barclays raised its price target on the company to $240 from $229, signaling continued confidence in the stock. See our full article here.

Is now the time to buy Tenet Healthcare? Access our full analysis report here.

Wynn Resorts : Luxury hotels and casino operator Wynn Resorts rose by 3.4% on Monday after Citigroup upgraded the company's stock to 'Buy' from 'Neutral' and significantly increased its price target. See our full article here.

Is now the time to buy Wynn Resorts? Access our full analysis report here.

Elevance Health : Health insurance provider Elevance Health rose by 2.1% on Monday after reports indicated the White House was preparing to unveil a health policy framework that would extend Affordable Care Act (ACA) premium subsidies for two years. See our full article here.

Is now the time to buy Elevance Health? Access our full analysis report here.

Merck : Global pharmaceutical company Merck rose by 4.1% on Monday after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the company's future. See our full article here.

Is now the time to buy Merck? Access our full analysis report here.

What Happened?

Shares of health insurance provider Elevance Health jumped 2.1% in the afternoon session after reports indicated the White House was preparing to unveil a health policy framework that would extend Affordable Care Act (ACA) premium subsidies for two years. 

The potential extension of these subsidies, also known as Obamacare, was viewed as a positive development for the health insurance industry. These government payments help people afford health insurance coverage, so continuing them would likely keep more customers enrolled in plans offered by companies like Elevance Health. The news prompted a broad rally among health insurers, with peers like Centene and Molina Healthcare also seeing their shares jump. The proposed policy framework reportedly included new eligibility limits alongside the two-year extension.

After the initial pop the shares cooled down to $332.39, up 3.3% from previous close.

Is now the time to buy Elevance Health? Access our full analysis report here.

What Is The Market Telling Us

Elevance Health’s shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The previous big move we wrote about was 13 days ago when the stock gained 4.1% on the news that the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied.This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia pulled back after SoftBank sold its stake. This "hurt the AI trade," dragging down related names like Micron and Oracle.As capital left tech, it sought safety in "higher quality" defensive names. Health care giants like Merck, Amgen, and Johnson & Johnson saw significant buying, boosting the Dow.

Elevance Health is down 9.1% since the beginning of the year, and at $332.39 per share, it is trading 26.6% below its 52-week high of $452.69 from April 2025. Investors who bought $1,000 worth of Elevance Health’s shares 5 years ago would now be looking at an investment worth $1,059.